Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Feasibility Study of the ReLeaf Catheter System (ReLeaf)

26 maart 2018 bijgewerkt door: Intervene, Inc.

A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein

This study is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Studie Overzicht

Toestand

Beëindigd

Interventie / Behandeling

Gedetailleerde beschrijving

The ReLeaf catheter system is intended for the creation of tissue leaflets in the deep veins where existing valve structures are no longer healthy and effectively moving blood.

This study aims to treat subjects with a documented history of symptomatic chronic venous insufficiency in whom compression therapy for at least 6 months, combined with superficial venous and/or perforator surgery have failed to obtain clinical improvement.

This clinical trial is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

2

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • History of symptomatic chronic venous insufficiency subjects, clinical category CEAP 3 or greater.
  • History of failed compression therapy (of at least 6 months), combined with superficial venous or perforator surgery.
  • Femoral and/or popliteal venous reflux of ≥ 1.0 seconds.
  • Deep system reflux with Kistner classification grade 2 or higher.
  • 18 years of age or older at the time of consent.
  • Willing and able to sign the Ethics Committee (EC) approved informed consent form.
  • Willing to comply with follow-up evaluations and protocols.

Exclusion Criteria:

  • In the Investigator's opinion, venous outflow obstruction that would inhibit adequate flow away from valve site.
  • Obstructive features in the femoral or popliteal vein below the proposed tissue leaflet creation site, which, in the Investigator's opinion, will not allow for sufficient blood flow to the tissue leaflet creation site.
  • Deep venous system intervention within 6 months of consent.
  • Obstructive features or irregularly small luminal diameter in the femoral vein which, in the opinion of the Investigator, will prohibit access to a tissue leaflet creation site.
  • Prior deep vein valve surgical intervention in the ipsilateral limb.
  • Ankle arthrodesis with secondary muscle atrophy or severely limited ambulation.
  • Limb-threatening circulatory compromise.
  • Contraindications to anticoagulation therapy that cannot be medically controlled.
  • History of symptomatic pulmonary embolism.
  • Acute venous thromboembolism within 3 months of consent.
  • Comorbidity risks which, in the opinion of the Investigator, limit longevity or likelihood of complying with protocol follow up.
  • General contraindications to surgery or the use of anesthesia.
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure.
  • Open Cardiac surgery (e.g. ventriculotomy, atriotomy) within the past 6 months of consent (Interventional procedures such as stenting or PTCA do not apply.)
  • Chronic Kidney Disease with creatinine level of 2mg/dL or higher.
  • Active systemic infection or sepsis.
  • Pregnant or lactating (positive pregnancy test, women of childbearing potential must be tested).
  • Appropriate vascular access is precluded.
  • Subject is enrolled in any other clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results.
  • Subject is considered at high risk for non-compliance with the protocol (e.g., inaccessible for follow-up).
  • Other invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results.
  • History of stroke within the last 6 months.
  • Subject is incarcerated or will be incarcerated during the course of the study.
  • Untreated significant superficial venous incompetence

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment
Subject to undergo the ReLeaf study procedure.
The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Andere namen:
  • Tissue Leaflet Creation, Creation of Valve-like Effect

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Technical Feasibility
Tijdsspanne: Day 0
Technical feasibility will be evaluated as the ability of the ReLeaf Catheter System to access the target site and successfully modify tissue as confirmed by, and in the opinion of, the Investigator. Successful target site access and confirmed tissue modification will be used as a measure of technical feasibility.
Day 0
Safety (The number of SAEs directly attributable to the study device will be used as a measure of safety)
Tijdsspanne: Day 30
Safety will be evaluated as freedom from serious adverse events directly attributed to the investigational device. The number of SAEs directly attributable to the study device will be used as a measure of safety.
Day 30

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Efficacy
Tijdsspanne: Day 365
Subsequent efficacy of the treatment following successful creation of the tissue leaflet(s). This will be measured through an assessment of tissue leaflet creation and the tissue leaflets ability to impact blood flow over the course of time.
Day 365
Durability
Tijdsspanne: Day 365
Long-term durability of the tissue leaflet(s). Confirmation of tissue leaflet existence over time will be used to assess the durability of the tissue leaflet.
Day 365
Long-term Safety (Long-term safety will be measured by freedom from SAEs directly attributable to the study device)
Tijdsspanne: Day 365
Further long-term safety data will be collected, analyzed and reported through the end of the study. Long-term safety will be measured by freedom from SAEs directly attributable to the study device.
Day 365

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 september 2015

Primaire voltooiing (Werkelijk)

8 oktober 2016

Studie voltooiing (Werkelijk)

5 juni 2017

Studieregistratiedata

Eerst ingediend

26 mei 2015

Eerst ingediend dat voldeed aan de QC-criteria

2 juni 2015

Eerst geplaatst (Schatting)

3 juni 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 maart 2018

Laatste update ingediend die voldeed aan QC-criteria

26 maart 2018

Laatst geverifieerd

1 maart 2018

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • CLP-0001

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op ReLeaf

3
Abonneren